These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35675968)

  • 21. Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer.
    Song MJ; Lee SH; Choi MR; Son HJ; Lee CW; Yoon JH; Park YG; Hur SY; Ryu KS; Lee JM
    Eur J Gynaecol Oncol; 2013; 34(2):148-51. PubMed ID: 23781586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
    Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
    Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
    J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
    Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
    Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
    Prayer L; Kainz C; Kramer J; Stiglbauer R; Schurawitzki H; Baldt M; Schima W; Poelzleitner D; Reinthaller A; Koelbl H
    J Comput Assist Tomogr; 1993; 17(4):626-32. PubMed ID: 8331235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA125 based diagnosis and therapy in recurrent ovarian cancer.
    Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3019-20. PubMed ID: 9329590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential blood count as triage tool in evaluation of pelvic masses.
    Cramer DW; Benjamin Iv WJ; Vitonis AF; Berkowitz R; Goodman A; Matulonis U
    Int J Gynecol Cancer; 2021 May; 31(5):733-743. PubMed ID: 32487682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study.
    Varughese E; Kondalsamy-Chennakesavan S; Obermair A
    J Ovarian Res; 2012 Mar; 5():11. PubMed ID: 22436532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
    Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
    Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to follow-up patients with epithelial ovarian cancer.
    Miller RE; Rustin GJ
    Curr Opin Oncol; 2010 Sep; 22(5):498-502. PubMed ID: 20498597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
    Innao P; Pothisuwan M; Pengsa P
    Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian cancer: the duplicity of CA125 measurement.
    Karam AK; Karlan BY
    Nat Rev Clin Oncol; 2010 Jun; 7(6):335-9. PubMed ID: 20368726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A joint model based on longitudinal CA125 in ovarian cancer to predict recurrence.
    Chang C; Chiang AJ; Chen WA; Chang HW; Chen J
    Biomark Med; 2016; 10(1):53-61. PubMed ID: 26565119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian fibroma/fibrothecoma with elevated serum CA125 level: A cohort of 66 cases.
    Shen Y; Liang Y; Cheng X; Lu W; Xie X; Wan X
    Medicine (Baltimore); 2018 Aug; 97(34):e11926. PubMed ID: 30142807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
    Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
    Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
    Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
    Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.